

Profiles
January 14, 2016

**NINA R. SCHOOLER, PH. D.
LIST OF PUBLICATIONS**

Original Communications in Peer Reviewed Journals:

Goldberg SC, Schooler NR, Davidson EM, and Kayce M. Sex and race differences in response to drug treatment among schizophrenics. Psychopharmacologia, 1966, 9:31-47.

Kellam SG, Goldberg SC, Schooler NR, Berman A, and Shmelzer J. Ward atmosphere and outcome of treatment of acute schizophrenia. Journal of Psychiatric Research, 1967, 5:145-163.

Schooler NR, Goldberg SC, Boothe H, and Cole JO. One year after discharge: community adjustment of schizophrenic patients. American Journal of Psychiatry, 1967, 123:986-995.

Goldberg SC, Schooler NR, and Mattsson N. Paranoid and withdrawal symptoms in schizophrenia: differential symptoms reduction over time. Journal of Nervous and Mental Disease, 1967, 145:158-162.

Goldberg SC, Schooler NR, and Mattsson N. Paranoid and withdrawal symptoms in schizophrenia: relationship to reaction time. British Journal of Psychiatry, 1968, 114:1161-1165.

National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group. Short-term improvement in schizophrenia: the contribution of background factors. American Journal of Psychiatry, 1968, 124:900-909.

Schooler NR, Boothe H, and Goldberg SC. Life history and symptoms in schizophrenia: severity at hospitalization and response to phenothiazines. Archives of General Psychiatry, 1971, 25:138-147. Reprinted in Annual Review of the Schizophrenic Syndrome (Cancro R, ed.) Bruner Mazel, New York, 1974, 327-346.

Boothe HH, Schooler NR, and Goldberg SC. Brief social history for studies in schizophrenia: an announcement of a new data collection instrument. Psychopharmacology Bulletin, 1972, 8:23-44.

Goldberg SC, Frosch WA, Drossman AK, Schooler NR, and Johnson GFS. Prediction of response to phenothiazines in schizophrenia: a cross-validation study. Archives of General Psychiatry, 1972, 26:367-373.

Schooler NR, and Goldberg SC. Performance tests in a study of phenothiazines in schizophrenia: caveats and conclusions. Psychopharmacologia, 1972, 24:81-98.

Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF, and the Collaborative Study Group. Drug and sociotherapy in the aftercare of schizophrenic patients: II. Two-year relapse rates. Archives of General Psychiatry, 1974, 31:603-608.

Hogarty GE, Goldberg SC, Schooler NR, and the Collaborative Study Group. Drug and sociotherapy in the aftercare of schizophrenic patients: III. Adjustments of nonrelapsed patients. Archives of General Psychiatry, 1974, 31:609-618.

Schooler NR, Levine J, and the NIMH-PRB Collaborative Fluphenazine Study Group. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmakopsychiatrie, 1976, 159-169.

Goldberg SC, Schooler NR, Hogarty GE, and Roper M. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry, 1977, 34:171-184.

Schooler NR, Collins PF, and Sakalis G. Statistical strategies for prediction of clinical response: performance tests as predictors of symptom reduction in psychopathology. Psychopharmacology Bulletin, 1978, 14:86-88.

Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, and Herron E. Depot fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled trial. Archives of General Psychiatry, 1979, 36:1283-1294.

Levine J, Schooler NR, and Cassano G. The role of depot neuroleptics in the treatment of schizophrenic patients. Psychological Medicine, 1979, 9:383-386.

Gelenberg AJ, Doller JC, Schooler NR, Mandel MR, and Mieske M. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. American Journal of Psychiatry, 1979, 136:217-219.

Schooler NR, Levine J, Severe J, Brauzer B, DiMascio A, Klerman G, and Tuason V. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Archives of General Psychiatry, 1980, 37:16-24.

Schooler NR. Neuroleptics and psychosocial treatments: a discussion. Schizophrenia Bulletin, 1980, 6 No. 1, 131-134.

Kane JM, and Schooler NR. Tardive dyskinesia workgroup report. Psychopharmacology Bulletin, 1980, 16, No. 1, 35-36.

Schooler NR. How generalizable are the results of clinical trials? Psychopharmacology Bulletin, 1980, 16, No. 1, 29-31.

- Schooler NR. Priorities for treatment assessment research (TAR) in clinical psychopharmacology. Psychopharmacology Bulletin, 1980, 16, No. 2, 29-31.
- Schooler NR, and Kane JM. Research diagnoses for tardive dyskinesia (RD-TD). Archives of General Psychiatry, 1982, 39:386-387.
- Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, and Mieske M. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Archives of General Psychiatry, 1982, 39:197-203.
- Schooler NR, and Levine J. Strategies for enhancing drug therapy of schizophrenia. American Journal of Psychotherapy, 1983, 38:521-531.
- Carpenter WT Jr, and Schooler NR. Eds. New drug treatment strategies in schizophrenia. Schizophrenia Bulletin, 1983, 9:500-562.
- Glazer WM, Moore DC, Schooler NR, Brenner LM, and Morgenstern H. Tardive dyskinesia: a discontinuation study. Archives of General Psychiatry, 1984, 41:623-627.
- Gibbons RD, Lewine RRJ, Davis JM, Schooler NR, and Cole JO. An empirical test of a Kraepelinian vs. a Bleulerian view of negative symptoms. Schizophrenia Bulletin, 1985, 11:390-395.
- Kane JM, Woerner M, Lieberman JA, Weinhold P, Florio W, Rubenstein M, Rotrosen J, Kurucz J, Mukherjee S, Bergmann K, and Schooler NR. The prevalence of tardive dyskinesia. Psychopharmacology Bulletin, 1985, 21:136-139.
- Schooler NR. The efficacy of antipsychotic drugs and family therapies in the maintenance treatment of schizophrenia. Journal of Clinical Psychopharmacology, 1986, 6:11S-19S.
- Levine J, and Schooler NR. SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacology Bulletin, 1986, 22:343-381.
- Alvir J, Schooler NR, Borenstein M, Woerner M, and Kane JM. The reliability of a shortened version of the SCL-90. Psychopharmacology Bulletin, 1986, 22:343-381.
- Schooler NR, and Prien RF. Introduction: Placebos in psychopharmacology clinical trials: Scientific and ethical issues. Psychopharmacology Bulletin, 1988, 24:3.
- Schooler NR. Research training for clinical trials in psychopharmacology. Psychopharmacology Bulletin, 1988, 24:303.
- Schooler NR. Evaluation of drug-related movement disorders in the aged. Psychopharmacology Bulletin, 1988, 24:603-607.
- Carpenter WT Jr, Schooler NR, Wise SW, et al. Treatment, services and environmental factors. Schizophrenia Bulletin, 1988, 14:427-438.

Schooler NR. Introduction: Establishing the efficacy and safety of psychopharmacologic drugs: The role of the Food and Drug Administration (FDA) and Industry. Psychopharmacology Bulletin, 1989, 25:3-4.

Schooler NR, Keith SJ, Severe JB, Matthews S., et al. Acute treatment response and short term outcome in schizophrenia: First results of the NIMH Treatment Strategies in Schizophrenia Study. Psychopharmacology Bulletin, 1989, 25(3):331-335.

Glick ID, Jacobs M, Lieberman J, Simpson G, Schooler NR, et al. Prediction of short term outcome in schizophrenia: Depressive symptoms, negative symptoms, and extrapyramidal signs. Psychopharmacology Bulletin, 1989, 25 (3):344-347.

Glazer WM, Morgenstern H, Schooler NR, Berkman CS and Moore DC. Predictors of improvement in Tardive Dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry, 1990, 157:585-592.

van Kammen DP, and Schooler NR. Are biochemical markers for treatment resistant schizophrenia state dependent or traits? Clinical Neuropharmacology, 1990, 13:Suppl. 1, 16-28.

Schooler NR. Maintenance Medication for Schizophrenia: Strategies for Dose Reduction. Schizophrenia Bulletin, 1991, 17, 311-323.

Grisso T, Baldwin E, Blanck PD, Rotheram-Borus JM, Schooler NR, Thompson T. Standards in Research: APA's Mechanism for Monitoring the Challenges. American Psychologist, 1991, 46, 758-766.

Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, Schooler NR, et al. The prevalence of tardive dyskinesia. Journal of Clinical Psychopharmacology, 1991, 11(1): 34-42.

Keshavan MS, Schooler NR. First episode studies in schizophrenia: Criteria and characterization. Schizophrenia Bulletin, 1992, 18:491-513.

Blanck PD, Bellack AS, Rosnow RL, Rotheram-Borus MJ, Schooler, NR. Scientific rewards and conflicts of ethical choices in human subjects research. American Psychologist, 1992, 47, 959-965.

Levine J, Schooler NR. General versus specific inquiry with SAFTEE. (Letters to the Editors), Journal of Clinical Psychopharmacology, 1992, 12(6), 448.

Baker RW, Chengappa KNR, Baird JW, Steingard S, Christ MAG, Schooler NR: Emergence of obsessive-compulsive symptoms during treatment with clozapine. Journal of Clinical Psychiatry, 1992, 53:439-442.

Schooler NR, Keith SJ. The clinical research base for the treatment of schizophrenia. Psychopharmacology Bulletin, 1993, 29, 431-446.

Myers DE, Schooler NR, Zullo TG, Levin H. A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia. Journal of Prosthetic Dentistry, 1993, 69:578-581.

McEvoy JP, Schooler NR, Friedman E, Steingard S, Allen M. Use of psychopathology vignettes by patients with schizophrenia or schizoaffective disorder and by mental health professionals to judge patients' insight. American Journal of Psychiatry 1993, 150:1649-1653.

Weiden P, Schooler NR, Severe JB, Lee JH, Schulz SC. Stabilization and depot neuroleptic dosages. Psychopharmacology Bulletin, 1993, 29, 269-275.

Schooler NR. Reducing dosage in maintenance treatment of schizophrenia: Review and prognosis. British Journal of Psychiatry, 1993, 163 (suppl 22), 58-65.

Schooler NR. Negative symptoms in schizophrenia: Assessment of the effect of risperidone. Journal of Clinical Psychiatry, 1994, 55, 5(suppl), 22-28.

Schooler NR. Editorial: Translating treatment research findings to clinical action. American Journal of Psychiatry, 1994, 151:12, 1719-1721.

Schooler NR. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatrica Scandinavica, 1994, 89, suppl 380, 21-26.

Chengappa KNR, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J. The prevalence of akathisia in patients receiving stable doses of clozapine. Journal of Clinical Psychiatry, 1994, 55:142-145.

Sanders RD, Keshavan MS, Schooler NR. Neurologic exam abnormalities in neuroleptic-naive, first-break schizophrenia: Preliminary results. American Journal of Psychiatry, 1994, 151:1231-1233.

Mueser KT, Sayers SL, Schooler NR, Mance RM, Haas GL. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms. American Journal of Psychiatry, 1994, 151:1453-1462.

Steingard S, Allen M, Schooler, NR. A study of the pharmacologic treatment of medication compliant schizophrenics who relapse. Journal of Clinical Psychiatry, 1994, 55:470-472.

Smith TE, Shea MT, Schooler NR, Levin H, Deutsch A, Grabstein E. Personality traits in schizophrenia. Psychiatry, 1995, 58:99-112.

Schooler NR, Keith SJ, Severe JB, Matthews SM. Maintenance treatment in schizophrenia: a review of dose reduction and family treatment strategies. Psychiatric Quarterly, 1995, 66(4): 279-292.

- Schooler NR. Integration of family and drug treatment strategies in the treatment strategies in the treatment of schizophrenia: a selective review. International Clinical Psychopharmacology, 1995, 10 (Suppl. 3): 73-80.
- Schooler NR, Severe JB, AGlick ID, Hargreaves WA, Keith SJ, Weiden P. Transition from acute to maintenance treatment: prediction of stabilization. International Clinical Psychopharmacology, 1996, 11 (suppl 2):85-91.
- Baker RW, Ames D, Umbricht DSG, Chengappa KNR, Schooler NR. Obsessive-compulsive symptoms in schizophrenia: A comparison of olanzapine and placebo. Psychopharmacology Bulletin, 1996, 32(1):89-93.
- Chengappa KNR, Gopalani A, Haught MK, McChesney K, Baker RW, Schooler NR. The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF). Psychopharmacology Bulletin, 1996, 32 (1):111-121.
- Schooler NR. Advances in maintenance treatment. Psychiatric Annals 1996, 26(8):519-522.
- Falloon IRH, McGill CW, Matthews SM, Keith SJ, Schooler NR. Family treatment for schizophrenia. Journal of Psychotherapy Practice and Research, 1996, 5:45-56.
- Schooler, NR. Letter to the Editor - Haloperidol Dosing Strategies. American Journal of Psychiatry, 1996, 153:1108-1109.
- Ames D, Wirshing WC, Baker RW, Umbricht DSG, Sun AB, Carter J, Schooler NR, Kane JM, Marder SR. Predictive value of eosinophilia for neutropenia during clozapine treatment. Journal of Clinical Psychiatry, 1996, 57(12):579-581.
- Sweeney JA, Bauer KS, Keshavan MS, Haas GL, Schooler NR, Kroboth PD. Adverse effects of risperidone on eye movement activity: A comparison of risperidone and haloperidol in antipsychotic-naïve schizophrenic patients. Neuropsychopharmacology, 1997, 16: 217-228.
- Carpenter WT, Schooler NR, Kane, JM. The rationale and ethics of medication-free research in schizophrenia. Archives of General Psychiatry, 1997, 54:401-407.
- Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG. Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment. Archives of General Psychiatry, 1997, 54:453-464.
- Schooler NR. New anti-psychotic medications: strategies for evaluation and selected findings. Schizophrenia Research, 1997, 27:249-259.
- Hogarty GE, Schooler NR, Baker RW. Psych. Services, 1998
- Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler NR, and Keith S. The development of treatment resistance in patients with schizophrenia: A clinical and

pathophysiologic perspective. Journal of Clinical Psychopharmacology, 1998, 18(2):20S-24S.

Schooler NR. What has research taught me about schizophrenia? The Journal of the California Alliance for the Mentally Ill, 1998, 9(1):68-69.

Schooler NR. Comments on article by Tran and Colleagues, A Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 1998, 18(2):174-175.

Sweeney JA, Luna R, Srinivasagam NM, Keshavan MS, Schooler NR, Haas GL, Carl JR. Eye tracking abnormalities in schizophrenia: evidence for dysfunction in the frontal eye fields. Biological Psychiatry, 1998, 44(8): 698-708.

Thompson J, Chengappa KNR, Good CB, Baker RW, Kiewe RP, Benzer J, and Schooler NR. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. International Clinical Psychopharmacology, 1998, 13(2):95-98.

Ahmed S, Chengappa KNR, Naidu VR, Baker RW, Parepally H, and Schooler NR. Clozapine withdrawal-emergent dystonias and dyskinesias: A case series. Journal of Clinical Psychiatry 1998, 59:472-477.

Kane JM, Aguglia E, Altamura AC, Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, and Schooler NR. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacological, 1998, 8(1):55-66.

Keshavan MS, Schooler NR, Sweeney JA, Haas GL, and Pettegrew JW. Research and treatment strategies in first-episode psychoses. British Journal of Psychiatry, 1998, 172(suppl 33):60-65.

Keshavan MS, Haas GL, Kahn CE, Aguilar E, Dick EL, Schooler NR, Sweeney JA, Pettegrew JW: Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? Journal of Psychiatric Research, 1998, 32(3-4): 161-167.

Barch DM, Carter CS, Perlstein W, Baird J, Cohen JD, Schooler N: Increased stroop facilitation effects in schizophrenia are not due to increased automatic spreading activation. Schizophrenia Research, 1999, 39(1): 51-64.

DeQuardo JR, Keshavan MS, Bookstein FL, Bagwell WW, Green WD, Sweeney JA, Haas GL, Tandon R, Schooler NR, Pettegrew JR. Landmark-based morphometric analysis of first-episode schizophrenia. Biological Psychiatry, 1999, 45(10): 1321-1328.

Chengappa KN, Sheth S, Brar JS, Parepally H, Marcus S, Gopalani A, Palmer A, Baker RW, Schooler NR: Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. Journal of Clinical Psychiatry, 1999, 60(6): 373-378.

Keshavan MS, Carter C, Haas G, Schooler NR: Schizophreniform disorder: exception probes the rule. American Journal of Psychiatry, 1999, 156(6): 971-972.

Robinson D, Woerner M, Schooler N. Intervention research in psychosis: issues related to clinical assessment. Schizophrenia Bulletin, 2000, 26(3):551-556.

Schooler NR, Fenton WS. Editors concluding remarks: psychosocial treatment: more than compassion and common sense? Schizophrenia Bulletin 2000, 26(1):153-155.

Fenton WS, Schooler NR. Evidence-based psychosocial treatment for schizophrenia. Schizophrenia Bulletin, 2000, 26(1): 1-3.

Fenton WS, Schooler NR. Editors= Introduction: Evident-Based Psychosocial Treatment for Schizophrenia. Schizophrenia Bulletin, 2000, 26:1-3.

Bellack AS, Haas GL, Schooler NR, Flory JD. Effects of behavioural family management on family communication and patient outcomes in schizophrenia. British Journal of Psychiatry, 2000, 177, 434-439.

Schooler NR, Fenton WS. Editors Concluding Remarks: Psychosocial Treatment: More Than Compassion and Common Sense?@ Schizophrenia Bulletin, 2000, 26:153-155.

Robinson D, Woerner MG, Schooler NR. Intervention research in psychosis: issues related to clinical assessment. Schizophrenia Bulletin 2000, 26:551-556.

Schooler NR. The statistical comparison of clinical trials. Journal of Clinical Psychiatry 2001,62 Suppl 9:35-7: discussion 38-9.

Mueser KT, Sengupta A, Schooler NR, Bellack AS, Xie H, Glick ID, Keith SJ. Family treatment and medication dosage reduction in schizophrenia: effects on patient social functioning, family attitudes, and burden Journal of Consulting and Clinical Psychology, 2001, 69(1):3-12

Schooler NR. The statistical comparison of clinical trials. J Clin Psychiatry. 2001, 62 Suppl 9:35-7

Kane JM, Marder SR, Schooler NR, Wirshing MC, Umbricht D, Baker RM, Wirshing DA, Safferman A, Ganguli R, Borenstein M, McMeniman M. Clozapine and haloperidol in moderately refractory schizophrenia: a six-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001, 58(10): 965-972.

Chengappa KN, Vasile J, Levine J, Ulrich R, Baker R, Gopalani A, Schooler N. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophrenia Research. 2002, 53(2-3): 1-6.

Umbricht DS, Wirshing WC, Wirshing DA, MCMeniman M, Schooler NR, Marder SR, Kane JM. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002, 63:420-424.

Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Leberman J, Schooler NR. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schiz Bulletin 2002, 28:5-16.

Kane JM, Davis JM, Schooler NR, Marder S, Casey D, Brauzer B, Mintz J, Conley R. A multicenter study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002, 159:554-560.

Schooler NR, O'Connor R. Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions. Schiz Research 2002, 53:1769.

Keshavan MS, Sanders RS, Sweeney J, Diwadkar VA, Goldstein G, Pettegrew JW, Schooler NR. Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first episode psychoses. Am J Psychiatry 2003,

Schooler NR.. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003, 64:13-16.

Schur SB, Sikich L, Findling RL and 9 others including Schooler NR. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAAY) Part I:a review. J Am Acad Child Adolesc Psychiatry 2003, 42:132-144.

Pappadopulos E, Macintyre I, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler NR et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAAY) Part II. J Am Acad Child Adolesc Psychiatry 2003, 42:145-161.

Bellack AS, Schooler NR, Marder SR, Kane JM et al. Clozapine and risperidone affect social competences and problem solving. Am J Psychiatry 2004, 161:364-367.

Marder SR, Essock SM, Miller AL & 21 others including Schooler NR. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161:1334-1349, 2004.

Miller AL, Hall CS Buchanan RW & 16 others including Schooler NR. The Texas Medication Algorithm Project algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004, 65:500-506

Keshavan MS, Rabinowitz J et al Schooler N. Correlates of insight in first episode schizophrenia, Schizophrenia Res 2004, 70:

Keshavan MS, Duggal HS, Veeragandham G, McLaughlin NM, Montrose DM, GL and Schooler NR. Personality dimensions in first-episode psychosis. Am J Psychiatry 2005, 162:102-109.

Schooler NR, Rabinowitz J et al. Long term effects of risperidone and haloperidol in first episode schizophrenia. Am J Psychiatry 2005;162:947-953.

McGurk S, Carter C, Goldman R, Green MF, Marder SR, Haiyi X, Schooler NR, Kane JM. The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry 2005, 162: 1013-1016.

Sevy S, Rosenthal M, Alvir J, Meyer S, Viswesvaraiiah H, Gunduz-Bruce H, Schooler NR. Double-blind, placebo controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medication. *J Clin Psychiatry* 2005. 66:839-843.

Gunduz-Bruce H, McMeniman M, Robinson D, Woerner M, Kane J, Schooler, N, Lieberman J. Duration of untreated psychosis and time to response for delusions and hallucinations. *Am J Psychiatry* 2005,

Robinson DR, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello SM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM. Randomized comparison of olanzapine and risperidone for first-episode schizophrenia: four month outcome. *Am J Psychiatry* 2006, 163:

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The cognitive and negative symptoms in schizophrenia trial (CONSIST); the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. *Am J Psychiatry* 2007;164:1593-1602.

Schooler NR. Efficacy and safety of conventional and atypical antipsychotics in first episode schizophrenia: a review of the literature. *Clin Schizophrenia and Related Psychoses*. 2007;1:27-38

Moore TA, Buchanan RW, Buckley PF; Chiles JA, Conley RR, Crismon LD, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL. The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia:2006 Update *J Clin Psychiatry* 2007, 68:

Deutsch SI, Schwartz BL, Schooler NR, Rosse RB, Mastropaolo J, Gaskins B. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained $\alpha 7$ nicotinic agonist strategy. *Clinical Neuropharmacology*, 2008;31:34-39.

Deutsch SI, Rosse RB, Schwartz BL, Schooler NR, Gaskins BL, Long KD, Mastropaolo J. Effects of CDP-Choline and the Combination of CDP-Choline and Galantamine Differ in an Animal Model of Schizophrenia: Development of a Selective $\alpha 7$ Nicotinic Acetylcholine Receptor Agonist Strategy. *European Journal of Pharmacology*, 2008, 18:147-151.

Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dube S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin S, Vermeulen A. What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? *Schizophrenia Bull* 2008, advance access on line August 22, 2008 doi:10.1093/schbul/sbn10h

Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V. Adjunctive divalproex sodium vs. placebo for children with ADHD and aggression refractory to stimulant monotherapy. *Am J Psychiatry*. 2009 166:1399-1401

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. Long-Acting Injectable Risperidone vs Continuation on Oral Atypical Antipsychotics for First-Episode Schizophrenia Patients: Initial RCT Adherence Outcomes. *J Clin Psychiatry*. 2009, 79:1397-1406.

Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. *Pediatrics* 2010;126(4):e796–e806

Canoso CM, Schooler N, Carrothers J, Turkoz I, Kosik-Gonzalez C, Bossie CA, Walling D, Lindenmayer JP. Paliperidone extended-release in schizo-affective disorder: a randomized controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. *J Clin Psychopharmacology* 2010, 30, 487-495.

Canoso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carrothers J, Bossie CA, Schooler N.
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizo-affective disorder. *J Clin Psychiatry* 2010, 71:587-598

Green MF, Schooler NR, Kern RS, Frese, FJ, Granberry W, Harvey PD, Karson CN, Peters N, Stewart M, Seidman LJ, Sonnenberg J, Stone WS, Walling D, Stover E, Marder SR. Evaluation of co-primary measures for clinical trials of cognition enhancement in schizophrenia. *Am J Psychiatry*, 2011:168:400-407

Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH. Effectiveness of switching from polypharmacy to monotherapy. *Am J Psychiatry* 2011 168; 702-708.

Weissman E, Jackson C, Schooler N, Goetz R, Essock E. Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication. *Clinical Schizophrenia and Related Psychoses*. 2012:7; 201-207.

Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson C, Rojas I, Essock SM. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres. *J Clin Psychiatry* 2012: 73;660-675.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A. Long-acting injectable medication maintenance treatment of “first-episode schizophrenia: a randomized effectiveness study. *J Clin Psychiatry* 2012:73;1224-1233.

Schooler NR: Can we incorporate psychosocial treatment interventions into psychopharmacology clinical trials? *J Clin Psychiatry*; 2012 Jul;73(7):1023-4 PMID: 22901351

Keefe RSE, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M. Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far? *Schizophrenia Bull* 2013; 39; 417-435

Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy. *Schizophrenia Res* 2013;148:138-144.

Chawla JM, Pal H, Lai R, Raka J, Schooler N, Balhara YPS. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin-dependent) subjects. *J Opioid Management* 2013;9:35-41.

Sapra M, Weiden PJ, Schooler NR, Sunakawa-McMillan A, Uzenoff S, Burkholder P. Reasons for adherence and non-adherence: a pilot study comparing first and multi-episode schizophrenia patients. *Clinical Schizophrenia and Related Psychoses*. 2014: Winter 199-206.

Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, M.D.Miller DD, Severe JB, Wilson DR, Ames D, Bustillo M, Mintz J, Kane JM. A Comparison of Second Generation Antipsychotic (SGA) Oral Medications versus a Long-Acting Injectable SGA: The PROACTIVE Study. *Schizophrenia Bull* 2014 doi: 10.1093/schbul/sbu067

Alphs L, Schooler N, Lauriello J. How study designs influence comparative effectiveness outcomes: The case of oral versus long-acting injectable antipsychotic treatment..., *Schizophr. Res.* (2014) <http://dx.doi.org/10.1016/j.schres.2014.04.024>

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck R, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Azrin S, Goldstein A, Severe JB, Heinssen R, Kane JM. Cardiometabolic Risk in First Episode Schizophrenia-Spectrum Disorder Patients: Baseline Results from the Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE-ETP) Study *JAMA Psychiatry* 2014 10 on line pub doi:10.1001/jamapsychiatry.2014.1314

Petrides G, Malur C, Braga R, Malhotra A, Shanghani S, John S, Goldberg T, Fink M, Schooler N, Kane J, Mendelowitz M. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia; a prospective, randomized study. *Am J Psychiatry* January 2015, Vol. 172, No. 1, pp. 52 - 58

Robinson DG, Schooler NR, Correll CU, Marcy P, Addington J, Brunette MF, Estroff SE, Mueser KT, Penn D, Robinson J, Rosenheck R, Severe J, Goldstein A, Azrin A, Heinssen R, Kane JM Medication Prescription Practices for the Treatment of First Episode Schizophrenia-Spectrum Disorders: Data from the National RAISE-ETP Study. *Am J Psychiatry* 2015 172(3), pp. 237-248
<http://dx.doi.org/10.1176/appi.ajp.2014.13101355>

Kane JM, Schooler NR, Marcy P, Correll CU, Brunette MF, Mueser KT, Rosenheck RA, Addington J, Estroff SE, Robinson J, Penn, DL, Robinson DG. The RAISE Early Treatment Program for First Episode Psychosis: Background, Rationale and Study Design. *J Clin Psychiatry* In Press

Addington J, Heinssen, R, Robinson DG, Schooler NR, Marcy P, Brunette MF, Correll

CU, Estroff S, Mueser KT, Penn D, Robinson J, Rosenheck RA, Azrin S, Goldstein A, Severe J, Kane JM. Duration of Untreated Psychosis in U.S. Community Treatment Settings *Psychiatric Services* In Press

Schooler NR, Buchanan RW, Laughren, Leucht S, Nasrallah HA, Potkin SG, Abi-Saab D, Galani Berardo Bugarski-Kirola D, Blaettler, Edgar CJ, Nordstroem A-L, O'Gorman C, Garibaldi G. Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. *Schizophrenia Res.* 2015 In Press

BOOKS, CHAPTERS IN BOOKS, REVIEW ARTICLES AND NON-PEER REVIEWED JOURNAL ARTICLES:

Boothe HH, Schooler NR, and Goldberg SC. Brief social history for studies in schizophrenia: an announcement of a new data collection instrument. *Psychopharmacology Bulletin*, 1972, 8:23-44.

Hogarty GE, Goldberg SC, and Schooler NR. Drugs and sociotherapy in the aftercare of schizophrenia: a review. In: Drugs in Combination with Other Therapies (Greenblatt M, ed) Grune and Stratton, New York, 1975, 1-12.

Schooler NR, Sakalis G, Chan TL, Gershon S, Goldberg SC, and Collins P. Chlorpromazine metabolism and clinical response in acute schizophrenia: a preliminary report. In: Pharmacokinetics of Psychoactive Drugs (Gottschalk L & Merlis S, eds.) Spectrum Publ., New York, 1976, 199-219.

Schooler NR. Antipsychotic drugs and psychological treatment in schizophrenia. In: Psychopharmacology -- A Generation of Progress. (Lipton MA, DiMascio A, and Killam KF, eds.) Raven Press, New York, 1978, 1155-1168.

Schooler NR, Collins PF, and Sakalis G. Statistical strategies for prediction of clinical response: performance tests as predictors of symptom reduction in psychopathology. *Psychopharmacology Bulletin*, 1978, 14:86-88.

Schooler NR, Hogarty GE, and Weissman MD. Social Adjustment Scale II (SAS). In: Resource materials for Community Mental Health Program Evaluations, edited by W.P. Hargreaves, C.C. Attkisson and J.E. Sorenson, US Department of Health, Education and Welfare, Rockville, MD, 1979, 290-302.

Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, and Steinbook R. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication. In: Long-term Effects of Neuroleptics: Pharmacological Basis and Clinical Implications. (Cattabeni et al, eds.) Raven Press, New York, 1980, 483-493.

Schooler NR. Placebo effect: From control to experimental condition. In: Perspectives in Schizophrenia Research. (Baxter C and Melnechuk T, eds.) Raven Press, New York, 1980, 389-395.

Levine J, and Schooler NR. Some epidemiological considerations in the design, conduct and interpretation of clinical trials of psychopharmacologic agents. In: Epidemiological Impact of Psychotropic Drugs. (Tognoni G, Bellantuono C, and Lader M, eds.) Elsevier/North-Holland, Biomedical Press, 1981, 377-390.

Schooler NR, Severe J, Levine J, Escobar J, Gelenberg A, Mandel M, Sovner R, and Steinbook R. Der abbruch der neuroleptischen behandlung bei schizophrenen patienten und dessen einfluss auf ruckfalle und auf symptome der spatdyskinesie. In: Ergebnisse der Psychiatrischen Therapieforschung (Kryspin-Exner K, Hinterhuber H, and Schubert H eds.) F.K. Schattauer Verlag, Stuttgart, 1982, 217-234.

Schooler NR. Discussion: Alternative drug treatment strategies in schizophrenia. In: Drug Maintenance Strategies in Schizophrenia (Kane JM, ed.). American Psychiatric Press, Inc., Washington, DC, 1984, 83-90.

Schooler NR, and Severe JB. Efficacy of drug treatment for chronic schizophrenic patients. In: The Chronically Mentally Ill: Research and Services, (Mirabi M, ed.). SP Medical and Scientific Books, New York, 1984, 125-142.

Schooler NR. Treatment of schizophrenia: maintenance strategies and pharmacologic tactics. In: Controversies in Schizophrenia (Alpert M, ed.). Guilford Press, New York, 1985, 366-380.

Schooler NR. Symptoms of psychopathology as predictors of relapse in schizophrenia. In: Predictors of Relapse in Schizophrenia (Lieberman JA and Kane JM, eds.). American Psychiatric Press Inc., Washington DC, 1986, 33-46.

Schooler NR, and Hogarty GE. Medication and psychosocial strategies in the treatment of schizophrenia. In: Psychopharmacology, The Third Generation of Progress (Meltzer H, ed.). Raven Press, New York, 1987, 1111-1119.

Keith SJ and Schooler NR. Treatment of Schizophreniform Disorder. In: Treatment of Psychiatric Disorders (Karasu TB, ed.), American Psychiatric Association, Washington, DC, 1989, 1666-1676.

Schooler NR, and Keith SJ. Role of Medications in Psychosocial Treatment. In: Handbook of Schizophrenia Volume 4: Psychosocial Treatment of Schizophrenia (Herz MI, Keith SJ and Docherty JP, eds.)_Elsevier Science Publishers B.V., Biomedical Division, 1990, 45-67.

Schooler NR, Keith SJ, Severe JB, Matthews S. Behandlungsstrategien bei Schizophrenie: Entwicklung einer Langzeitstudie. In H Hinterhuber, F Kulhankek, WW Fleischhacker (Eds), Kombination therapeutischer Strategien bei schizophrenen Erkrankungen. Friedr. Vieweg Verlag, Braunschweig: Wiesbaden 1990, 131-160.

Keith SM, Matthews SM, Schooler NR. A review of psychoeducational family approaches. In: Advances of Neuropsychiatry and Psychopharmacology, Volume 1: Schizophrenia Research (Tamminga CA and Schulz SC, Eds.) Raven Press, Ltd., New York, 1991, 247-254.

Keith SJ, Schooler NR. Psychosocial and psychotherapeutic strategies for long-term treatment of schizophrenia. In: International Review of Psychiatry (Costa e Silva JA, Nadelson CC, eds.). American Psychiatric Press, Inc., Washington, DC, 1993, pp 229-262.

Schooler NR. Anti-psychotic medications and schizophrenia: Their effects in acute and maintenance treatment of the illness. In: Schizophrenia: Origins, Processes, Treatment, and Outcome (Cromwell RL. & Snyder CR Eds.) Oxford University Press, New York, 1993, pp 284-295.

Schooler NR, Rickels, K (Eds.) Section III. Specific Patient Groups: Application of General Methodologic Principles. In: Clinical Evaluation of Psychotropic Drugs (Prien RF, Robinson DS Eds.) Raven Press, 1994.

Kane JM, Schooler NR, Marder SR, Simpson GM, Casey DE. Methods for Clinical Evaluation of Pharmacologic Treatments of Schizophrenia. In: Clinical Evaluation of Psychotropic Drugs (Prien RF, Robinson DS Eds.) Raven Press, 1994, pp 345-372.

Kaufmann CL, Schulberg HC, Schooler NR. Self-help group participation among people with severe mental illness. In Prevention in Human Services, The Haworth Press, Inc., 1994, pp 315-331.

***Robinson DS, Schooler, NR. Clinical Study Design - Critical Issues. In: Psychopharmacology: the Fourth Generation of Progress CD:ROM (Bloom FE and Kupfer DJ eds). 1997, In press.

***Schooler NR, Baker RW. Providing quality care in the context of clinical research. In: Informed Consent: A Resource Manual for Investigators (Pincus HA ed), American Psychiatric Press, Inc. 1997, In press.

Schooler NR. Group comparisons: Randomized designs. In: Comprehensive Clinical Psychology (Bellack AS and Hersen M eds), Elsevier Science, 1998, pp47-61.

Schooler NR. Research and Methods (Volume 3 - Schooler NR ed). In: Comprehensive Clinical Psychology (Bellack AS and Hersen M eds), Elsevier Science, 1998, pp1-380.

Schooler NR, Baker RW. Providing quality care in the context of clinical research. In: Ethics in Psychiatric Research: A Resource Manual for Human Subjects Protection (Pincus HA, Lieberman JA, and Ferris S eds), American Psychiatric Press, Inc., Washington, DC, 1999, pp 61-80.

Robinson DS, Schooler NR. Clinical Study Design - Critical Issues. In: Psychopharmacology: the Fourth Generation of Progress CD:ROM (Bloom FE and Kupfer DJ eds). 1999.

Schooler NR, Chengappa KNR. Adverse effects measures. In: Handbook of Psychiatric Measures (Rush AJ, Pincus HA, First MB et al eds). American Psychiatric Association, Washington CD, 2000, pp 151-168.

Gunduz H, Schooler NR. Side effects in psychopharmacology. In: International Encyclopedia of the Social and Behavioral Sciences (Smelser NJ and Baltes PB eds). Pergamon - Elsevier Science, In press.

Schooler NR. Chapter 2. Interventions for non-optimal responders. In: Marder S. Editor Switching Antipsychotic Medication. Science Press Ltd, London. 2000

Schooler NR. Maintaining symptom control: review of ziprasidone long-term efficacy data. J Clin Psychiatry 2006; 64 supplement

Schooler NR. Commentary: Implications for future research of "Medication-free research in early episode schizophrenia. Schizophrenia Bulletin, 2006. 32, 297-298.

Schooler NR. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry 2006 supplement

Nina R.Schooler
January 4, 2016